When was BigHat founded?

BigHat was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is BigHat located?

BigHat is headquartered in San Carlos, United States.

How many employees does BigHat have?

As of Jul 31, 2026, the latest employee count at BigHat is 96.

Is BigHat a funded company?

BigHat is a funded company, having raised a total of $148M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 19, 2019.

When was the latest funding round of BigHat?

BigHat's latest funding was a $***** Series B round on Jun 30, 2022, with participation from 9 investors.

Where does BigHat rank among its competitors?

BigHat ranks 26th amongst 213 active competitors, of which 67 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Chai Discovery, which secured $400M in Jul, 2026.

Who are the top competitors of BigHat?

BigHat's top competitors include argenx, Alexion and Chai Discovery. Among them, Chai Discovery secured the most recent funding round in July, 2026.

BigHat - 2026 Company Profile, Team, Funding & Competitors

BigHat is a series B company based in San Carlos (United States), founded in 2019 by Peyton Greenside. It operates as a Provider of antibody therapies developed by machine learning and synthetic biology. BigHat has raised $148M in funding from Andreessen Horowitz and S32. The company has 213 active competitors, including 67 funded and 63 that have exited. Its top competitors include companies like argenx, Alexion and Chai Discovery.

Company Details

Provider of antibody therapies developed by machine learning and synthetic biology. The company offers an AI-enabled antibody design platform named Milliner, that offers antibody therapies to treat intractable conditions like chronic illnesses to life-threatening diseases.

Website: www.bighatbio.com/
Social
Email ID: *****@bighatbio.com

Key Metrics

Founded Year

2019

Location

San Carlos, United States

Stage

Series B

Total Funding

$148M in 3 rounds

Latest Funding Round

Series B, Jun 30, 2022, $*****

Investors

Andreessen Horowitz & 14 more

Ranked

26^th among 213 active competitors

Employee Count

96 as on Jul 31, 2026

Investment & Acquisitions

Frugi

Similar Companies

argenx & 256 more

View BigHat's full profile

BigHat has raised a total funding of $148M over 3 rounds. Its first funding round was on Dec 19, 2019. Its latest funding round was a Series B round on Jun 30, 2022 for $*****. 9 investors participated in its latest round. BigHat has 15 institutional investors.

Here is the list of recent funding rounds of BigHat:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 30, 2022	2894662	Series B	3020357	4485427	5065311	9087327
Feb 10, 2021	6137000	Series A	2952420	8142263	1019648	8VC & 2 more
Dec 19, 2019	9705628	Series A	4529279	2950178	5483968	4033738

Access funding benchmarks and valuations. Sign up today!

View details of BigHat's funding rounds and investors

The founders of BigHat is Peyton Greenside.

Here are the details of BigHat's key team members:

Peyton Greenside: Co-founder and CSO of BigHat.
Contact Info: 1 email address

View details of BigHat's Founder profiles and Board Members

BigHat's employee count trend

BigHat has 96 employees as of Jul 26. Here is BigHat's employee count trend over the years:

Uncover BigHat's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of BigHat include argenx, Alexion and Chai Discovery. Here is the list of Top 10 competitors of BigHat, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
2nd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
3rd	Chai Discovery 2023, San Francisco (United States), Series C	Developer of artificial intelligence models for de novo molecular design	$630M	Kleiner Perkins, Oak HC/FT & 28 others	69/100
4th	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, Third Security & 8 others	67/100
5th	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	HongShan, Kleiner Perkins & 9 others	67/100
6th	Antiverse 2017, Cardiff (United Kingdom), Series A	Developer of computational platform for de novo design of antibody therapeutics	$20M	Kadmos Capital, ACF Investors & 34 others	67/100
7th	XOMA Corporation 1981, Berkeley (United States), Acquired	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, Hercules Capital & 5 others	65/100
8th	Adimab 2007, Lebanon (United States), Series F	Antibody discovery and optimization platform for autoimmune and infectious diseases	$35.4M	Polaris Partners, SV Health Investors & 10 others	65/100
9th	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	63/100
10th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	63/100
26th	BigHat 2019, San Carlos (United States), Series B	Provider of antibody therapies developed by machine learning and synthetic biology	$148M	Amgen Business Development, AME Cloud Ventures ... & 13 others	57/100